Source: Annual Congress 2006 - Sarcoidosis



Rating:

Share or cite this content

Citations should be made in the following way:
N. V. Refiskaya, T. A. Stepanenko, P. K. Jablonskiy, O. P. Baranova (St. Petersburg, Russian Federation). The use of tumor necrosis factor alpha inhibitor pentoxifylline in the treatment of patients with I and II stages of pulmonary sarcoidosis. Eur Respir J 2006; 28: Suppl. 50, 3134

Member's Comments

No comment yet.

Related content which might interest you: Screening and monitoring of tuberculosis in patients on tumor necrosis factor antagonist therapy Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Effects of oxygen supplementation on the secretion of tumour necrosis factor alpha (TNFα) in hypoxaemic COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 209s Year: 2001 Risk of chemotherapy-induced pulmonary fibrosis is associated with polymorphic tumour necrosis factor-a2 gene Source: Eur Respir J 2002; 19: 912-918 Year: 2002 Pulmonary lesions in patients with inflammatory bowel disease – the baseline and under anti-tumor necrosis factor therapy. Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Levels of plasma tumour necrosis factor and soluble tumour necrosis factor receptor in patients with COPD and its relation to glucocorticoid receptor levels Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Tumor necrosis factor alpha inhibitors and reactivation of tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 281s Year: 2007 The risk of tuberculosis related to tumour necrosis factor antagonist therapies Source: Annual Congress 2011 - TBNET: tuberculosis research in Europe Year: 2011 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1510-1512 Year: 2015 Screening for latent tuberculosis before tumour necrosis factor antagonist therapy Source: Eur Respir J 2015; 45: 1512-1513 Year: 2015 Measurement of tumour necrosis factor converting enzyme (TACE) activity on alveolar macrophages from healthy subjects and subjects with inflammatory lung disease Source: Eur Respir J 2002; 20: Suppl. 38, 417s Year: 2002 Association of the TNF gene promoter polymorphism with serum tumor necrosis factor-alpha levels in chronic obstructive pulmonary disease patients Source: Eur Respir J 2006; 28: Suppl. 50, 522s Year: 2006 Tumour necrosis factor receptor-75 and risk of COPD exacerbation in the azithromycin trial Source: Eur Respir J 2014; 43: 295-298 Year: 2004 Serum leptin and tumor necrosis factor – alpha levels and maximal exercise performance in patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Respiratory muscles in disease Year: 2008 Evaluation levels of pro-inflammatory cytokines tumour necrosis factor (TNF)-alpha and interferon (IFN)-gamma in lung cancer complicated with metastatic pleurisy Source: Eur Respir J 2001; 18: Suppl. 33, 233s Year: 2001 Mycobacterial diseases developed during anti-tumour necrosis factor alpha therapy Source: Eur Respir J 2014; 44: 1289-1295 Year: 2014 Radiographic changes in patients with tumor necrosis factor alpha inhibitor and immunomodulatory drug users: Four years follow up Source: International Congress 2016 – Mixed-up imaging of various chest diseases Year: 2016 The use of symbicort in the treatment of patients with I and II stages of pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 85s Year: 2007 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Source: Eur Respir J 2010; 36: 1185-1206 Year: 2010 Analysis of tumor necrosis factor receptor 1 (TNFR1) polymorphisms in patients with cryptogenic fibrosing alveolitis Source: Eur Respir J 2001; 18: Suppl. 33, 411s Year: 2001